Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Funda Meric-Bernstam, Michael W. Lloyd, Soner Koc, Yvonne A. Evrard, Lisa M. McShane, Michael T. Lewis, Kurt W. Evans, Dali Li, Lawrence Rubinstein, Alana Welm, Dennis A. Dean, Anuj Srivastava, Jeffrey W. Grover, Min J. Ha, Huiqin Chen, Xuelin Huang, Kaushik Varadarajan, Jing Wang, Jack A. Roth, Bryan WelmRamaswamy Govinden, Li Ding, Salma Kaochar, Nicholas Mitsiades, Luis Carvajal-Carmona, Meenhard Herylyn, Michael A. Davies, Geoffrey I. Shapiro, Ryan Fields, Jose G. Trevino, Joshua C. Harrell, James H. Doroshow, Jeffrey H. Chuang, Jeffrey A. Moscow

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.

Original languageEnglish
Pages (from-to)924-938
Number of pages15
JournalMolecular Cancer Therapeutics
Volume23
Issue number7
DOIs
StatePublished - Jul 2024

Fingerprint

Dive into the research topics of 'Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations'. Together they form a unique fingerprint.

Cite this